SPY330.06+1.27 0.39%
DIA268.41+1.69 0.63%
IXIC10,941.17+38.37 0.35%

Credit Suisse Downgrades Allena Pharmaceuticals to Neutral, Lowers Price Target to $4

Credit Suisse downgrades Allena Pharmaceuticals (NASDAQ:ALNA) from Outperform to Neutral and lowers the price target from $7 to $4.

Benzinga · -

Credit Suisse downgrades Allena Pharmaceuticals (NASDAQ:ALNA) from Outperform to Neutral and lowers the price target from $7 to $4.